Cover Image
市場調查報告書

C型肝炎:全球臨床實驗趨勢

Hepatitis C Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 222299
出版日期 內容資訊 英文 1564 Pages
訂單完成後即時交付
價格
Back to Top
C型肝炎:全球臨床實驗趨勢 Hepatitis C Global Clinical Trials Review, H2, 2017
出版日期: 2017年09月15日 內容資訊: 英文 1564 Pages
簡介

本報告提供C型肝炎相關臨床研究之最新趨勢分析,提供您疾病·治療方法概要,及G7各國的臨床實驗狀況,各地區、各階段的進展狀況,並彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量:亞太地區
    • 前五名國家的臨床實驗數量:歐洲
    • 主要國家的臨床實驗數量:北美
    • 前五名國家的臨床實驗數量:中東/非洲地區
    • 前五名國家的臨床實驗數量:中南美

G7各國的臨床實驗數量:C型肝炎臨床實驗數量佔感染疾病臨床實驗數量比率

各期臨床實驗數量:G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:C型肝炎臨床實驗數量佔感染疾病臨床實驗數量比率

各期臨床實驗數量:E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

各評估項目臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - C型肝炎治療藥

有潛力的藥劑

最新臨床實驗新聞:C型肝炎

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4571CTIDB

GlobalData's clinical trial report, "Hepatitis C Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis C clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis C. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Hepatitis C Therapeutics Clinical Trials 30
  • Prominent Drugs 32
  • Latest Clinical Trials News on Hepatitis C 33
  • Aug 17, 2017: Gilead Receives Approval in Canada for VOSEVI (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection 33
  • Aug 16, 2017: The Lancet Infectious Diseases publishes Phase 3 data showing 99 percent of adults with chronic hepatitis C infection and compensated cirrhosis achieved virologic cure with AbbVie's glecaprevir/pibrentasvir 33
  • Aug 15, 2017: Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection 34
  • Clinical Trial Profile Snapshots 35

Appendix 1562

  • Abbreviations 1562
  • Definitions 1562
  • Research Methodology 1563
  • Secondary Research 1563
  • About GlobalData 1564
  • Contact Us 1564
  • Source 1564

List of Tables

List of Tables

  • Hepatitis C Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Hepatitis C Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Hepatitis C Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Hepatitis C Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
  • GlobalData Methodology 1563
Back to Top